|
|
|
| Effect of Modified Shenqi Dihuang Decoction Combined with Alprostadil on Patients with Chronic Renal Failure |
| MA Hao, WANG Chun-li, ZHANG Hui-min, et al |
| Department of Nephrology,Baoji Hospital of traditional Chinese Medicine,Baoji Shaanxi 721000 |
|
|
|
|
Abstract 【Objective】 To investigate the effects of modified Shenqi Dihuang Decoction combined with alprostadil on renal function, inflammatory indexes and the level of advanced protein oxidation products (AOPP) in patients with chronic renal failure. 【Methods】 A total of 100 patients with chronic renal failure treated in our hospital were randomly divided into traditional Chinese medicine group (50 cases) and Western medicine group (50 cases). The western medicine group was treated with alprostadil, and the traditional Chinese medicine group was treated with modified Shenqi Dihuang Decoction combined with alprostadil. The changes of renal function [serum creatinine (SCR), urea nitrogen (BUN), 24h urinary protein], AOPP level, inflammatory indexes [C-reactive protein (CRP), interleukin-17 (IL-17), interleukin-6 (IL-6)] and clinical efficacy and adverse reactions were compared between the two groups. 【Results】 Compared with before treatment, serum SCR, BUN, 24h urinary protein, AOPP, CRP, IL-17 and IL-6 decreased significantly in the two groups after treatment (P<0.05), and the decrease in the traditional Chinese medicine group was more obvious than that in the western medicine group (P<0.05); The total effective rate of traditional Chinese medicine group was 86.00% (43/50), which was significantly higher than that of Western medicine group [62.00% (31/50) (P<0.05)]; There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】 The modified Shenqi Dihuang Decoction combined with alprostadil in the treatment of chronic renal failure can effectively regulate the inflammatory indexes, reduce the level of AOPP, improve renal function and oxidative stress, and is safe and effective.
|
|
Received: 17 October 2021
|
|
|
|
|
|
[1] 张云,施书涵,车丽双,等.缬沙坦联合前列地尔治疗慢性肾小球肾炎患者的临床研究[J].中国临床药理学杂志,2020,21(12):1614-1616.
[2] 屈志刚.参芪地黄汤加减联合西药治疗慢性肾功能衰竭疗效观察[J].实用中医内科杂志,2019,33(7):58-61.
[3] 林淑媛,刁金囡.参芪地黄汤加减治疗慢性肾脏病的临床疗效分析[J].中医临床研究,2019,11(22):111-113.
[4] 陈香美,倪兆慧,刘玉宁,等.慢性肾衰竭中西医结合诊疗指南[J].中国中西医结合杂志,2015,38(9):1029-1033.
[5] 郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:12.
[6] COULTHARD M G. The management of neonatal acute and chronic renal failure:A review[J].Early Hum Dev,2016,102(21):25-29.
[7] 关岩.前列地尔联合羟苯磺酸钙治疗慢性肾衰竭的疗效[J].实用医学杂志,2018,34(6):1043-1045.
[8] 房娜,李平,张晓瑜.苏叶地黄汤联合前列地尔对慢性肾衰竭患者肾功能、血清炎症因子及脂代谢指标的影响[J].现代中西医结合杂志,2019,28(16):1732-1735.
[9] 申正日,李仁武.参芪地黄汤合解毒活血汤治疗慢性肾功能不全气阴两虚兼血瘀证的效果观察[J].临床误诊误治,2016,21(B6):80-81.
[10] HU X L,ZENG W J,LI M P,et al. AGXT2 rs37369 polymorphism predicts the renal function in patients with chronic heart failure[J].Gene,2017,30(637):145-151.
[11] 王祝娟,强博.杏丁注射液联合前列地尔治疗慢性肾衰竭患者的临床研究[J].药物评价研究,2020,43(9):211-214.
[12] WANG J.Change of peripheral blood Treg/Thl7 in cognitive impairment with chronic renal failure patients[J].Cell Physiol Biochem,2018,45(1):281-290. |
|
|
|
2022, Vol. 39 
